Man-14
CMFTe003-A
General
Cell Line |
|
| hPSCreg name | CMFTe003-A |
| Cite as: | CMFTe003-A (RRID:CVCL_BW68) |
| Alternative name(s) |
Man-14
|
| Cell line type | Human embryonic stem cell (hESC) |
| Similar lines | No similar lines found. |
| Last update | 3rd August 2020 |
| User feedback | |
Provider |
|
| Generator | Central Manchester and Manchester Children's University Hospitals NHS (CMFT) |
| Owner | Central Manchester NHS Foundation Trust (CMFT) |
| Distributors | |
| Derivation country | United Kingdom |
External Databases |
|
| BioSamples | SAMEA104619828 |
| Cellosaurus | CVCL_BW68 |
| Wikidata | Q54903990 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Clinical use: allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Is the medical history available upon request? | Yes |
| Is clinical information available? | Yes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Array CGH
|
External Databases (Donor) |
|
| BioSamples | SAMEA7274739 |
Ethics
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| How may genetic information associated with the cell line be accessed? | |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | HTA, HFEA, and UK Stem Cell Bank |
| Approval number | HTA Licence number: 22627, HFEA Licence number: R0171-4-b. UKSCB approval number: SCSC14-23 |
hESC Derivation
| Date of derivation | 2011-09-05 |
| Embryo stage | Blastula with ICM and Trophoblast |
| Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
| PGD Embryo? |
No |
| Expansion status |
2
|
| ICM morphology |
B
|
| Trophectoderm morphology |
a
|
| ZP removal technique | Chemical |
| Cell isolation | Mechanical |
| Cell seeding | Isolated ICM |
| Derived under xeno-free conditions? |
No |
| Derivation under GMP? |
Yes |
| Available as clinical grade? |
Yes |
Culture Conditions
| Surface coating | CELLstart | |||||||||
| Feeder cells |
Human Dermal Fibroblast Cellfinder Ont Id: CELDA_000001419 |
|||||||||
| Passage method | Mechanically | |||||||||
| O2 Concentration | 20 % | |||||||||
| CO2 Concentration | 5 % | |||||||||
| Medium |
mTeSR™ 2
Supplements
|
|||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Unknown |
|||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Unknown |
|||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| SSEA-1 |
No |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| GATA Binding Protein 6 |
Yes |
| FOXA2 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| Actin, Alpha 2, Smooth Muscle, Aorta |
Yes |
| Vimentin |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| Tubulin Beta 3 Class III |
Yes |
| Neurofilament, light polypeptide |
Yes |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal Female 46 XX
Passage number: 20
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Array CGH
|
Login to share your feedback, experiences or results with the research community.